Computed tomography characteristics of lung adenocarcinomas with epidermal growth factor receptor mutation: A propensity score matching study

被引:21
作者
Suh, Young Joo [1 ,2 ,3 ]
Lee, Hyun-Ju [1 ,2 ]
Kim, Young Jae [4 ]
Kim, Kwang Gi [4 ]
Kim, Heekyung [1 ,2 ]
Jeon, Yoon Kyung [5 ]
Kim, Young Tae [6 ]
机构
[1] Seoul Natl Univ Hosp, Dept Radiol, 101 Daehak Ro, Seoul 03080, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Radiol, 103 Daehak Ro, Seoul 03080, South Korea
[3] Yonsei Univ, Severance Hosp, Coll Med, Dept Radiol, Seoul, South Korea
[4] Gachon Univ, Coll Med, Dept Biomed Engn, Incheon, South Korea
[5] Seoul Natl Univ Hosp, Dept Pathol, Seoul, South Korea
[6] Seoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Dept Thorac & Cardiovasc Surg,Coll Med, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Lung adenocarcinoma; EGFR mutation; Computed tomography; SOCIETY/EUROPEAN RESPIRATORY SOCIETY; MOLECULAR TESTING GUIDELINE; GROUND-GLASS OPACITY; EGFR MUTATION; INTERNATIONAL ASSOCIATION; PULMONARY ADENOCARCINOMA; BRONCHIOLOALVEOLAR CARCINOMA; HISTOLOGIC SUBTYPES; CANCER PATIENTS; K-RAS;
D O I
10.1016/j.lungcan.2018.06.030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: We investigated the relationship between computed tomography (CT) characteristics and epidermal growth factor receptor (EGFR) mutations in a large Asian cohort who received surgical resection of invasive lung adenocarcinoma. Materials and Methods: We retrospectively included 864 patients (524 with EGFR mutation and 340 with EGFR wild-type) who received surgical resections for invasive lung adenocarcinomas. After applying propensity score matching, 312 patients with mutated EGFR were matched with 312 patients with wild-type EGFR. CT characteristics, predominant histologic subtype, and CT measurement parameters (volume and estimated diameter of the total tumor and inner solid portion and ground-glass opacity [GGO] proportion) were compared within matched pairs. Results: Tumors in the EGFR mutation group showed higher proportions of pure ground-glass nodules (4.1% vs 1.3%), GGO-predominant (23.7% vs 14.7%), and solid-predominant part-solid nodules (37.2% vs 31.7%) CT characteristics, whereas EGFR wild-type tumors predominantly presented as pure solid nodules (34.6% vs 52.2%, P < 0.0001). EGFR mutation tumors more frequently had a lepidic-predominant subtype than did EGFR wild-type tumors (20.2% and 11.9%; P < 0.0001), and showed a smaller whole tumor size and solid portion (P < 0.0001) with a higher GGO proportion (P < 0.0001). Tumors with exon 21 missense mutations showed the highest GGO proportion and the smallest inner solid portion size, followed by tumors harboring an exon 19 deletion, compared with EGFR wild-type tumors (posthoc P < 0.01). Conclusion: Adenocarcinomas with EGFR mutations had a higher GGO proportion than those with wild-type EGFR after matching of clinical variables. Lesions with an exon 21 mutation had a higher GGO proportion than lesions with other mutations.
引用
收藏
页码:52 / 59
页数:8
相关论文
共 46 条
[1]   FCM - THE FUZZY C-MEANS CLUSTERING-ALGORITHM [J].
BEZDEK, JC ;
EHRLICH, R ;
FULL, W .
COMPUTERS & GEOSCIENCES, 1984, 10 (2-3) :191-203
[2]   CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis [J].
Cheng, Zenghui ;
Shan, Fei ;
Yang, Yuesong ;
Shi, Yuxin ;
Zhang, Zhiyong .
BMC MEDICAL IMAGING, 2017, 17
[3]   Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma [J].
Ebright, MI ;
Zakowski, MF ;
Martin, J ;
Venkatraman, ES ;
Miller, VA ;
Bains, MS ;
Downey, RJ ;
Korst, RJ ;
Kris, MG ;
Rusch, VW .
ANNALS OF THORACIC SURGERY, 2002, 74 (05) :1640-1647
[4]   Comparison of FISH, PCR, and Immunohistochemistry in Assessing EGFR Status in Lung Adenocarcinoma and Correlation With Clinicopathologic Features [J].
El-Zammar, Ola A. ;
Zhang, Shengle ;
Katzenstein, Anna-Luise A. .
DIAGNOSTIC MOLECULAR PATHOLOGY, 2009, 18 (03) :133-137
[5]   Radiomics: Images Are More than Pictures, They Are Data [J].
Gillies, Robert J. ;
Kinahan, Paul E. ;
Hricak, Hedvig .
RADIOLOGY, 2016, 278 (02) :563-577
[6]   The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours [J].
Goldstraw, Peter ;
Crowley, John ;
Chansky, Kari ;
Giroux, Dorothy J. ;
Groome, Patti A. ;
Rami-Porta, Ramon ;
Postmus, Pieter E. ;
Rusch, Valerie ;
Sobin, Leslie .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) :706-714
[7]   Correlation Between EGFR Mutation Status and Computed Tomography Features in Patients With Advanced Pulmonary Adenocarcinoma [J].
Hsu, Jui-Sheng ;
Huang, Ming-Shyan ;
Chen, Chiao-Yun ;
Liu, Gin-Chung ;
Liu, Ta-Chih ;
Chong, Inn-Wen ;
Chou, Shah-Hwa ;
Yang, Chih-Jen .
JOURNAL OF THORACIC IMAGING, 2014, 29 (06) :357-363
[8]   Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection [J].
Jeon, Jae Hyun ;
Kang, Chang Hyun ;
Kim, Hye-seon ;
Seong, Yong Won ;
Park, In Kyu ;
Kim, Young Tae .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2015, 47 (03) :556-562
[9]   Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update [J].
Kalemkerian, Gregory P. ;
Narula, Navneet ;
Kennedy, Erin B. ;
Biermann, William A. ;
Donington, Jessica ;
Leighl, Natasha B. ;
Lew, Madelyn ;
Pantelas, James ;
Ramalingam, Suresh S. ;
Reck, Martin ;
Saqi, Anjali ;
Simoff, Michael ;
Singh, Navneet ;
Sundaram, Baskaran .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) :911-+
[10]   Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations [J].
Kim, Tae Jung ;
Lee, Choon-Taek ;
Jheon, Sang Hoon ;
Park, Jeong-Soo ;
Chung, Jin-Haeng .
ANNALS OF THORACIC SURGERY, 2016, 101 (02) :473-480